Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

213 та иш

Иш: Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology

  1. Polymeric Nanoparticles for Drug Delivery

    Maximilian A. Beach, Umeka Nayanathara, Yanting Gao +4

    Шарҳ мақола20247 иқтибос
    ABI

  2. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Мақола20215 иқтибос
    ABI

  3. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity

    Wenyan Fu, Changhai Lei, Shuowu Liu +12

    Мақола20194 иқтибос
    ABI

  4. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

    Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis +6

    Мақола20174 иқтибос
    ABI

  5. The paths and challenges of “off-the-shelf” CAR-T cell therapy: An overview of clinical trials

    Vahid Moradi, Azadeh Omidkhoda, Naser Ahmadbeigi

    Шарҳ мақола20234 иқтибос
    ABI

  6. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

    Vahid Moradi, Elnaz Khodabandehloo, Mehdi Alidadi +2

    Шарҳ мақола20244 иқтибос
    ABI

  7. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

    Zhenguang Wang, Na Li, Kaichao Feng +14

    Мақола20213 иқтибос
    ABI

  8. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth

    Pengxiang Yang, Xingjian Cao, Huilong Cai +7

    Мақола20203 иқтибос
    ABI

  9. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21

    Мақола20183 иқтибос
    ABI

  10. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

    Na Tang, Chen Cheng, Xingying Zhang +6

    Мақола20203 иқтибос
    ABI

  11. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32

    Мақола20183 иқтибос
    ABI

  12. Current hurdles to the translation of nanomedicines from bench to the clinic

    Snežana Đorđević, María Medel Gonzalez, Inmaculada Conejos‐Sánchez +6

    Шарҳ мақола20213 иқтибос
    ABI

  13. Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery

    Jialiang Wang, Yaopeng Ding, K. Chul Chong +7

    Шарҳ мақола20243 иқтибос
    ABI

  14. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani +33

    Мақола20213 иқтибос
    ABI

  15. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy

    Eleonora Pinto, Lisa A. Lione, Mirco Compagnone +8

    Шарҳ мақола20253 иқтибос
    ABI

  16. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype

    Darya Alizadeh, Robyn A. Wong, Xin Yang +11

    Мақола20192 иқтибос
    ABI

  17. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

    Maria‐Luisa Schubert, Michael Schmitt, L. Wang +4

    Шарҳ мақола20202 иқтибос
    ABI

  18. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

    Yongxian Hu, Yali Zhou, Mingming Zhang +25

    Мақола20222 иқтибос
    ABI

  19. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

    Hollie J. Pegram, James Lee, Erik Hayman +4

    Мақола20122 иқтибос
    ABI

  20. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i>

    Mythili Koneru, Terence J. Purdon, David R. Spriggs +2

    Мақола20152 иқтибос
    ABI

  21. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo

    Jinge Zhou, Lei Sun, Yujie Jia +8

    Мақола20222 иқтибос
    ABI

  22. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

    Christian Flugel, Robbie G. Majzner, Giedre Krenciute +4

    Шарҳ мақола20222 иқтибос
    ABI

  23. IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

    Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey +4

    Мақола20232 иқтибос
    ABI

  24. Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering

    Ke Si, Zhu Dai, Zhanping Li +6

    Мақола20232 иқтибос
    ABI

  25. CAR-T cell-derived exosomes: a new perspective for cancer therapy

    Farnaz Sani, Shabnam Shojaei, Seyed Amirhossein Tabatabaei +4

    Шарҳ мақола20242 иқтибос
    ABI